Healthy Skepticism Library item: 13169

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Kmietowicz Z.
Company accused of exploiting unique features of drug to retain market share
BMJ 2008 Mar 15; 336:(7644):576
http://www.bmj.com/cgi/content/extract/336/7644/576-a

Abstract:

Doctors, governments, and drug regulators must watch the way drug companies operate because the dearth of new medicines is taking profit chasing to new heights, an expert has warned.

Joe Collier, emeritus professor of drug policy at St George’s, University of London, issued his advice in the wake of an investigation by the BBC’s Newsnight programme, which suggested that Reckitt Benckiser, the makers of Gaviscon (sodium alginate and potassium bicarbonate), maintained an effective monopoly on the market for years after the drug came off patent.

The investigation, which was broadcast last Friday, claimed that the company had created obstacles to block rival manufacturers from selling cheaper generic copies, resulting in there still being no generic version of Gaviscon almost 10 years after the product’s patent expired in 1999.

A former employee turned whistleblower claimed on Newsnight that the company had “cheated the NHS” and that a generic formulation of Gaviscon . . .